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Abstract
Transthyretin (TTR) is one of thirty non-homologous proteins whose misfolding, dissociation, aggregation, and deposition is
linked to human amyloid diseases. Previous studies have identified that TTR amyloidogenesis can be inhibited through
stabilization of the native tetramer state by small molecule binding to the thyroid hormone sites of TTR. We have evaluated
a new series of b-aminoxypropionic acids (compounds 5–21), with a single aromatic moiety (aryl or fluorenyl) linked
through a flexible oxime tether to a carboxylic acid. These compounds are structurally distinct from the native ligand
thyroxine and typical halogenated biaryl NSAID-like inhibitors to avoid off-target hormonal or anti-inflammatory activity.
Based on an in vitro fibril formation assay, five of these compounds showed significant inhibition of TTR amyloidogenesis,
with two fluorenyl compounds displaying inhibitor efficacy comparable to the well-known TTR inhibitor diflunisal. Fluorenyl
15 is the most potent compound in this series and importantly does not show off-target anti-inflammatory activity. Crystal
structures of the TTR:inhibitor complexes, in agreement with molecular docking studies, revealed that the aromatic moiety,
linked to the sp2-hybridized oxime carbon, specifically directed the ligand in either a forward or reverse binding mode.
Compared to the aryl family members, the bulkier fluorenyl analogs achieved more extensive interactions with the binding
pockets of TTR and demonstrated better inhibitory activity in the fibril formation assay. Preliminary optimization efforts are
described that focused on replacement of the C-terminal acid in both the aryl and fluorenyl series (compounds 22–32). The
compounds presented here constitute a new class of TTR inhibitors that may hold promise in treating amyloid diseases
associated with TTR misfolding.
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Introduction
Transthyretin (TTR) is a homotetrameric protein, consisting of
four 127-amino acid b-sheet-rich subunits [1], and is present in
mammals, birds, and reptiles [2]. Human TTR is involved in the
transport of thyroxine (T4) in the cerebrospinal fluid and is a
secondary carrier of T4 in plasma; approximately half of the TTR
tetramer population in plasma is bound to retinol binding protein
(RBP) [1,3,4,5,6,7,8]. TTR normally circulates as an innocuous
soluble protein, but in some individuals it polymerizes to form
amyloid fibrils. The fibrils are formed through a mechanism which
most likely consists of a preliminary misfolding of the TTR
tetramer [9,10,11], followed by self-assembly into amyloid fibrils
[12,13]. The result is the formation of insoluble toxic fibrillar
deposits associated with many diseases. Four types of amyloidosis
have been observed: senile systemic amyloidogenesis (SSA)
[14,15], familial amyloid cardiomyopathy (FAC) [15], familial
amyloid polyneuropathy (FAP) [16], and central nervous system-
selective amyloidosis (CNSA) [17,18]. SSA results from the
fibrillization of wild-type TTR fibril in elderly individuals
[14,15], whereas the origins of the familial diseases (FAC, FAP,
and CNSA) are thought to be rooted in the fibrillogenesis of TTR
mutants found in diverse populations all over the world [19]. In
familial diseases, amyloid fibril aggregation may principally
determine serious pathologies, including systemic and central
neuropathies and cardiomyopathies leading to severe, life-
threatening conditions [20].
TTR related amyloidogenesis lacks an effective therapy, although
it has been observed [21] that amyloid fibril formation is prevented
by the binding of the small molecule T4. Thus, stabilization by T4
analogs may underline a possible therapeutic strategy. However, the
hormonal activities of T4 and its close analogs represent a safety
concern. Previous reports in the literature have disclosed several
small molecule families, typically sharing the halogenated biaryl
motif, which stabilize the TTR tetramer [8,22,23,24,25]. These
families include several nonsteroidal anti-inflammatory drugs
(NSAIDs) with an arylpropionic, acetic or benzoic acid moiety
(Figure 1), such as flurbiprofen (1 or FLP) [22], diclofenac (2) [24],
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flufenamic acid (FLU) (3) [22], and diflunisal (4) [25,26] which
significantly inhibit TTR fibril formation.
X-ray crystallographic studies have provided a rationale for the
stabilization of the native state of TTR by T4 hormone, while
offering insights into novel inhibitor designs [4,8,22,27]. Previous
reports of the TTR tetramer structure depicted two funnel-shaped
binding sites in the T4 hormone, each defined by its dimer–dimer
interface [4,22]. Figure 2a depicts the tetrameric TTR and
Figure 2b shows the close-up view of the hormone binding pocket.
A junction of four Ser117 side chains may be observed, situated at
the interface between the two identical T4 binding sites. Each
hormone binding site can be divided into an inner and outer
Figure 1. (left) General structure of NSAID inhibitors of TTR amyloidosis (1–4) and schematic representation of their common
pharmacophoric portions. (Right) The two different types of spacer between the pharmacophoric portions present in synthesized compounds 5–
32 of Table 1 and Table 2 with general formula A and classical NSAIDs with aryl–propionic structure, respectively.
doi:10.1371/journal.pone.0006290.g001
Figure 2. The T4 hormone binding channel of TTR tetramer. (a) Ribbon diagram of tetrameric structure of TTR with bound compound 15 (see
results and discussion section). Each subunit (labeled A, B, C and D) of the tetramer is shown with its secondary structural elements and colored
differently. The binding of 15 in both T4 binding pockets of TTR is shown as a stick model inside a transparent surface. The crystallographic
asymmetric unit contains subunits A and B while subunits C and D were formed through crystallographic symmetry. Because of the two-fold axis
along the binding channel (indicated by the arrows) a second symmetry-related binding conformation is present for the inhibitor molecule in both
hormone binding sites. (b) Definition of the halogen binding pockets (HBPs) of the T4 hormone binding site of TTR based on the previously published
crystal structure of T4 bound to the protein (PDB 1ROX) [4]. T4 is shown in both of its symmetry-related binding modes (shown in magenta and green
inside the molecular surface mesh) that are related by a two-fold rotation axis. The carboxyl tail of T4 is positioned at the entry port of the binding site
(outer binding pocket) and the iodines occupy the HBP1, HBP2, and HBP3 pockets. The inner binding pocket, HBP3, is located between the side
chains of Ser117, Thr119, Ala108, and Leu110, the central HBP2 pocket is formed by the side chains of Leu17, Ala108, Ala109 and Leu110 and the
outer pocket HBP1 is located between the side chains of Lys15, Leu17, Thr106 and Val121.
doi:10.1371/journal.pone.0006290.g002
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binding cavity. Six halogen binding pockets (HBP1, HBP1’,
HBP2, HBP2’, HBP3 and HBP3’) were also defined within each
hormone binding pocket based on the positions of the halogen
atoms of T4 in the TTR:T4 crystal structure, Figure 2b [4,22].
The inner binding cavity comprises HBP3 and HBP3’, formed by
the side chains of Ser117, Leu110, Thr119 and Ala108 of both
subunits. The Ser117 hydroxyl groups mediate hydrogen bond
interactions with bound inhibitors, as detailed in previously
reported TTR:inhibitor complex structures [8,22,28]. The outer
binding site is composed of HBP1 and HBP1’, formed primarily
by residues Lys15, Leu17, Thr106, and Val121 of both subunits.
HBP2 and HBP2’ are positioned at the interface of the inner and
outer binding cavities, comprising residues Leu17, Ala108, Ala109
and Leu110 of both subunits. The associated binding pocket is
highly lipophilic allowing the HBP2 and HBP2’ residues to
interact favorably with the hydrophobic portions of inhibitors.
Typically, TTR inhibitors and T4 bind in what is referred to as
the forward binding mode, where anionic substituents like
carboxylate are positioned in the outer binding pocket engaging
in electrostatic interaction with the Lys15 e-ammonium groups.
However, the reverse binding mode, with the carboxylate oriented
towards the inner binding pocket to hydrogen bond with Ser117
and Ser117’, is not unusual and has also been observed previously
in TTR complexed with diclofenac (a biarylamine), several
diclofenac analogues, and some diflunisal analogs [24,25,29].
A common pharmacophore among small molecule stabilizers of
the T4 hormone binding pocket of TTR tetramer is a carboxylic
acid connected through a rigid spacer to an aromatic moiety
(Figure 1). Based on the co-crystal structure, Zanotti et al. have
shown that all-trans-retinoic acid, a cyclohexene-linker-acid com-
pound, binds to TTR in a forward binding mode similar to thyroxine
[30]. However, to the best of our knowledge, the aryl-linker-acid
architecture has not previously been utilized for TTR tetramer
stabilization. Here in this study, we have evaluated a series of
previously synthesized b-aminoxypropionic acids [31,32,33] (com-
pounds 5–21 in Figure 3 and Table 1), as TTR amyloid inhibitors.
These compounds contain a flexible oxime-based tether between the
aromatic (aryl or fluorenyl) and acidic moieties. At the outset of this
investigation, we hypothesized that the greater flexibility of the
oxime ether tether could allow these small molecule ligands to more
fully occupy the volume of the TTR hormone binding pocket. The
effect of the bulkiness of the aromatic moiety was also probed with
respect to inhibitor efficacy and ligand binding mode. The
diversification from the typical biaryl system was designed to yield
inhibitors devoid of off-target anti-inflammatory activity, as previous
TTR inhibitor designs are roughly equipotent inhibitors of both
TTR [22,34] and cyclooxygenase (prostaglandin endoperoxide
synthase or COX 1–3) enzymes [35,36,37]. For example, FLP
binds to TTR, COX-1 and COX-2 with similar sets of interactions
and inhibits both TTR amyloidosis (70% inhibition at 7.2 mM),
COX-1 (IC50 = 0.41 mM) and COX-2 (IC50 = 4.2 mM) enzyme
activity [22,36]. Based on the TTR:FLP complex crystal structure,
we have hypothesized that the bulkier compounds may bind
specifically to TTR without inhibiting COX-1, characterized by
comparatively smaller hydrophobic binding pockets [22]. Specifi-
cally, we suggested that the bulkier substituents projecting into the
HBP1 and HBP2 regions of the TTR:FLP pocket might significantly
improve TTR-inhibitor interactions and reduce its binding affinity
for COX-1 and COX-2 due to steric hindrance. In fact, replacement
of the phenyl ring in the NSAIDs biaryl system with a bulkier
carborane moiety greatly decreased their COX activity with the
significant inhibitor efficacy of TTR dissociation [34,38].
An in vitro TTR amyloid fibril formation assay was utilized to
evaluate compound efficacy and the three-dimensional crystal
structures of TTR in complex with four inhibitors were solved.
Molecular docking was harnessed in concert with X-ray structural
studies to examine the relationship between inhibitor chemical
structure, efficacy, and binding mode. In an attempt to initiate the
further optimization of these TTR inhibitors, novel compounds
with longer chain substitutions and enhanced flexibility were
prepared (Figure 4 and Table 2): b-aminoxymethylsulfonylpropio-
namides (compounds 22–27), (b-aminoxypropanamido) acetic
acids (compounds 28–30), and (b-aminoxypropanamido) propanoic
acids (compounds 31 and 32). Based on the in vitro assay, three of
these compounds exhibited significant inhibition against TTR
amyloid fibrils providing a basis for the further exploration of SAR.
Results
Design and Synthesis of Aryl and Fluorenyl Families
A common pharmacophore among small molecule stabilizers
(including 1–4) of the TTR amyloidosis is a carboxylic acid
connected through a rigid spacer to an aromatic moiety (Figure 1).
Based on these potent TTR inhibitors, the new series of
compounds (5–21 in Figure 3 and 22–32 in Figure 4) were
chosen for the current investigation. The rationale for these
compounds involves two novel variations on the structures of
previously known inhibitors: 1) the aryl moiety, displaying the
carboxylate group, of the typical biaryl inhibitors is replaced by the
C = N-O-C type linker and 2) the other ring structure in the biaryl
scaffold is examined as either an aryl or fluorenyl moiety. It is
noteworthy that the bulkier fluorenyl group has not been explored
previously in this context.
The b-aminoxypropionic acids 5–21 were synthesized as
previously reported in the literature [31,32,33]. The b-aminoxy-
N-(methylsulfonyl)propionamides (22–27), the (b-aminoxypropa-
namido)acetic acids (28–30), and the (b-aminoxypropanamido)-
propanoic acids (31 and 32) were prepared as outlined in Figure
S1 of the Supplementary material. In general, the condensation of
b-aminoxypropionic acids with methanesulfonamide in the
presence of dicyclohexylcarbodiimide and a catalytic amount of
4-dimethylaminopyridine in dimethylformamide afforded the
desired compound, purified by crystallization. Reaction of the
appropriate b-aminoxypropionic acids with the hydrochloride salt
of the ethyl ester of glycine- or b-alanine in dimethylformamide in
the presence of triethylamine and O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium tetrafluoroborate gave the corresponding
ethyl esters 33–35, 36, and 37, respectively. The ethyl esters 33
and 37 thus obtained and subjected to alkaline hydrolysis to afford
the desired acetic acids 28–30 or propanoic acids 31 and 32.
TTR amyloid fibril inhibition studies
Table 1 reports the percent inhibition of TTR fibrillization by an
equimolar concentration of b-aminoxypropionic acid 5–21 inhib-
itor. It should be noted that this concentration was chosen to be that
of TTR in plasma [8]. Of the 17 compounds tested, 3 compounds
(13, 15, 16) showed more than 50% inhibition while 11 and 20
demonstrated 43% inhibition of TTR amyloidogenesis. The
inhibitors may be divided into two different groups: compounds
5–15, which lack a substituent in the carboxyl a-position, and
compounds 16–21, which have an a-methyl group (16–19) or an a-
methoxyimino group (compounds 20 and 21). Notably, fluorenyl
compounds 15 and 16 displayed inhibition of TTR fibril formation
comparable to the well-known TTR amyloid inhibitor diflunisal
(69% for 15 and 16Vs 63% inhibition for diflunisal [25]), while ortho-
substituted aryl derivatives 11 and 13 were slightly less efficacious.
The biological results for the new b-aminoxy-N-(methylsulfonyl)
propionamides (compounds 22–27), the (b-aminoxy-propana-
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mido) acetic acids (compounds 28–30) and the (b-aminoxy-
propanamido) propanoic acids (31, 32) are reported in Table 2.
Three out of 11 compounds (24, 26, and 27) showed significant
inhibitory activity. Again, a fluorenyl family member, compound
26, displayed the most potent activity (65%), with an ortho-
substituted analog (24) also exhibiting good activity.
Time course of TTR amyloid fibril inhibition for fluorenyl
compounds 15, 16, and 20
Although the inhibitor efficacy of 15 and 16 at 3.6 mM was
comparable to that of diflunisal, previous studies have shown that at
7.2 mM concentration the potency of diflunisal is increased from
63% to 96% [25]. Therefore, we evaluated 15, 16 and 20 further at
7.2 mM concentration, monitoring the fibril formation at the 0, 24,
48, 72 and 96 hours time points (Figure 5) in three independent runs
for each compound. All three inhibitors exhibited more than 90%
inhibition and significantly suppressed fibril formation. Of the three
tested compounds, 15 displayed the best inhibition (94%).
Crystal structures of inhibitors 11, 13, 15 and 16 bound to
TTR
High-resolution X-ray crystal structures of 11, 13, 15 and 16
bound to wt-TTR were obtained by soaking TTR crystals with a
fivefold molar excess of inhibitor for 3–4 weeks. Compounds 11
and 13 were selected for crystal structure investigation as they
showed significant inhibitory activity and represent the aryl family,
while the two most potent inhibitors in this report (compounds 15
and 16) are members of the fluorenyl class. In each case, the
crystals diffracted to approximately 1.8 A˚ resolution and the
crystal data and refinement statistics for each complex structure
are reported in Table 3. The overall molecular structure of the
TTR:inhibitor complexes are very similar to that of native TTR.
Figure 2a shows the binding of 15 to both hormone binding
pockets of the TTR tetramer. There are two hormone binding
Figure 3. Structures of b-aminoxypropionic acid compounds evaluated in this study.
doi:10.1371/journal.pone.0006290.g003
Table 1. In vitro acid-mediated wt-TTR (3.6 mM)
amyloidogenesis inhibition activity of compounds 5–21 (see
Figure 3).
Compound % inhibition ( 3.6 mM inhibitor)
diflunisal (4) 6365
5 2761.1
6 1260.51
7 1960.89
8 1762.8
9 1660.030
10 1360.30
11 4360.63
12 060.37
13 5162.4
14 1762.1
15 6966.5
16 6963.2
17 060.51
18 2761.5
19 2360.41
20 4360.04
21 3660.62
The percentage fibril formation was assessed by turbidity measurements at
400 nm, pH 4.4. TTR amyloidogenesis in the absence of inhibitor was assigned
to be 100%. The inhibition by diflunisal [25] is included as a reference from the
previously published work. For each compound, the inhibition is reported as
the mean6standard error, from three independent determinations.
doi:10.1371/journal.pone.0006290.t001
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sites per tetramer (AC between the subunits A and C, and BD
between the subunits B and D), each of which has an intrinsic two-
fold symmetry as these are located on the crystallographic two-fold
axis (indicated by an arrow in Figure 2a). All TTR:inhibitor
complex structures showed significant additional electron density
in both hormone binding pockets, confirming binding of the
inhibitor. The electron density corresponding to the inhibitor
observed in the inner and outer hormone binding pockets of the
BD dimer is well ordered in the crystal structures with compounds
11, 13, 15, and 16. (Figures 6 and 7). In contrast, the electron
density of the carboxyl substituted region of these inhibitors is only
partially ordered in the AC dimer (Figures 6a, 6b, 7a and 7b). The
observed electron density for the substituted region and the clear
electron density for the side chain atoms of the protomer allowed
us to finalize the binding modes in both the AC and BD dimers
without ambiguity. Moreover, similar electron density differences
between the two hormone binding pockets have been observed in
many of the previously reported structures including the
TTR:oxime-ether crystal structure [39].
Binding of 11 to wt-TTR
Compound 11 binds to TTR in the forward binding mode, with
the carboxylate-substituted hydrophilic chain oriented in the outer
binding pocket to interact with Lys15 and Lys15’ (Figures 6a and
6c). In each hormone binding site, two different binding
conformations of the ligand were identified with approximately
equal occupancy (shown in magenta and green in Figures 6a and
6c). In the inner binding pocket of the BD dimer, the aryl ring is
stacked between the hydrophobic side chains of Ala108, Ala108’,
Leu110, Leu110’, Thr119 (through Cc), and Thr119’ (also
through Cc). The trifluoromethyl substituent occupies halogen
binding pocket 3 (HBP3) in the inner cavity. One of the fluorine
atoms of the trifluoromethyl substituent makes what may be
termed as a favorable through space electrostatic interaction
[40,41] with the backbone amide N-H of Leu110 and Leu110’ at a
distance of 2.9 A˚. In both the AC and BD dimers, Ser117 and
Ser117’ orient their hydroxyl groups away from the inhibitor,
contributing to additional hydrophobic interactions with the aryl
moiety of the inhibitor via their b-CH2 groups (the C6 carbon
atom of the aryl moiety of 11 is at 3.3 A˚ distance from Cb carbon
atom of Ser117). An ordered water molecule (labeled W1 in
Figure 6a) is located between the adjacent Ser117 residues of the
AC dimer facilitating hydrogen bonding interactions between the
serine Oc atoms (Ser117 Oc-W1-Ser117’ Oc at a distance of
2.8 A˚) and is not involved in any direct interactions with the
inhibitor. However, the side chain of Thr119 and Thr119’ of the
AC dimer makes adjustments by adopting two conformations and
contributes to additional hydrophobic and hydrogen bond
interactions (Oc atom is at 2.9 A˚ and Cc atom is at 3.3 A˚ from
the closest fluorine atom of 11) with the inhibitors. The multiple
conformations of Thr119 are not observed in the BD dimer, but
all other interactions of the inner binding pocket are very similar in
both the AC and BD dimers. The electron density of the linker
atoms is well ordered in the BD dimer and only partially ordered
Figure 4. Structures of b-aminoxymethylsulfonylpropionamides (compounds 22–27), (b-aminoxypropanamido) acetic acids
(compounds 28–30), and (b-aminoxypropanamido) propanoic acids (compounds 31 and 32) evaluated in this study.
doi:10.1371/journal.pone.0006290.g004
Table 2. In vitro acid-mediated wt-TTR (3.6 mM)
amyloidogenesis inhibition activity of compounds 22–32 (see
figure 4).
Compound % inhibition ( 3.6 mM inhibitor)
Diflunisal (4) 6365
22 065.8
23 1760.37
24 5661.2
25 064.6
26 6562.3
27 5963.5
28 263.8
29 060.99
30 1560.99
31 1061.3
32 1066.5
The percentage fibril formation was assessed by turbidity measurements at
400 nm, pH 4.4. TTR amyloidogenesis in the absence of inhibitor was assigned
to be 100%. The inhibition by diflunisal [25] is included as a positive control. For
each compound, the inhibition is reported as the mean6standard error, from
three independent determinations.
doi:10.1371/journal.pone.0006290.t002
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in the AC dimer. The electron density of the carboxylate group of
the inhibitor is clearly visible. In both dimers, the linkers are
stabilized by the side chains of residues Leu17, Leu17’ (the closest
distance from the inhibitor is 3.3 A˚), Ala108, Ala108’ (at 3.9 A˚
distance). However, in both inhibitor binding pockets, the linker
oxygen and nitrogen atoms do not appear to make hydrogen bond
Figure 5. In vitro acid-mediated wt-TTR (3.6 mM) fibril formation in the presence of 7.2 mM inhibitors are shown plotted with wt-TTR
control. Fibril formation was assessed by turbidity measurments at 0, 24, 48, 72 and 96 hours time points at 400 nm, pH 4.4. For each compound,
the inhibition values are reported as the mean value (less than65standard error), from three independent determinations.
doi:10.1371/journal.pone.0006290.g005
Table 3. X-ray Crystallographic Data for inhibitor bound TTR structures.
TTR:11 (PDBd ID: 3GLZ) TTR:13 (PDB ID: 3GS7) TTR:15 (PDB ID: 3GS4) TTR:16 (PDB ID: 3GS0)
Data collection
Unit cell (A˚) 42.18, 84.94, 63.42 42.17, 84.76, 63.81 43.18, 85.73, 64.77 43.39, 85.98, 65.08
Space group P21212 P21212 P21212 P21212
Number of molecules in ASU (Z) 2 2 2 2
Resolution limit (A˚) 63.37-1.8 63.76-1.8 64.82-1.8 86.07-1.9
Completeness (%) 99.5(98.9) 99.4 (98.2) 99.6 (98.9 ) 98.7 (97.7)
I/sIa 39.5 (8.5) 16.5 (3.0) 24.7 (6.9) 14.4 (3.4)
Rsym
b (%) 2.8 (16.8) 5.2 (32) 3.8(19.0) 9.0 (56.8)
Structure Refinement
Resolution limit (A˚) 63.37-1.8 63.76-1.8 64.82-1.8 86.07-1.9
Completeness (%) 99.5(98.9) 99.4 (98.2) 99.6 (98.9 ) 98.7 (97.7)
Rcryst
c (%) 22.4 22.4 22.5 22.9
Rfree
c (%) 27.3 26.6 27.8 26.9
Number of protomer residues in ASU 220 225 223 224
Disordered residues A1–A9, A125–A127, B1–B9,
B37–B38, B101–B103,
B124–B127
A1–A9, A125–A127, B1–B9,
B124–B127
A1–A9, A125–A127, B1–B9,
B100–B102, B125–B127
A1–A9, A125–A127, B1–B9,
B101–B102, B125–B127
Average B factor (A˚2) 31.6 40.2 32.8 38.8
RMS deviations from the ideal values
Bond lengths (A˚) 0.016 0.019 0.014 0.020
Bond angles (u) 1.8 1.9 1.8 2.2
Ramachandran statistics (PROCHECK[52])
Most favored (%) 92.7 89.9 91.9 89.2
Allowed (%) 7.3 10.1 8.1 10.8
Values in parentheses are for high resolution shells.
aI/sig = the mean I/sig for the unique reflections in the output file.
bRsym =ghgi | Ihi2ÆIhæ|/ghgi Ihi, where Ihi is the ith observation of the reflection h, whereas ÆIhæ is the means intensity of reflection h.
cRcryst =g|Fo|2|Fc|/|Fo|. Rfree was calculated with a fraction (5%) of randomly selected reflections excluded from refinement.
dProtein Data Bank (www.rcsb.org).
doi:10.1371/journal.pone.0006290.t003
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interactions with TTR. The electron density map of all binding
pocket residues was clear and well ordered. However, Lys15 and
Lys15’ of the AC and BD dimers showed weak electron density,
indicating their flexibility, with their best fit conformations placing
the Ne atom at hydrogen bonding distance (3.0 A˚) from the
carboxyl substituent of the inhibitor.
Binding of 13 to wt-TTR
Substitution of a methoxy group in place of the trifluoromethyl
in compound 11 does not significantly affect the binding mode of
13 to TTR, while affording a slightly more potent inhibitor.
Compound 13 binds to TTR in the forward binding mode
(Figure 6b) with the carboxyl-substituted hydrophilic chain
oriented in the outer binding pocket towards residues Lys15 and
Lys15’. The electron densities of the aryl ring and linker atoms of
the inhibitor are well ordered in the BD dimer and only partially
ordered in the AC dimer. Thus, the binding interactions are
described for the BD dimer bound inhibitor. In both T4 hormone
binding pockets, the inhibitor adopts two conformations with
equal occupancy (shown in magenta and green in Figure 6b). In
both binding conformations, the methoxy substituent at the ortho-
position of the aryl ring of 13 protrudes into halogen binding
pockets 3 and 39. The oxygen atom of the ortho-O-methyl group of
13 forms a hydrogen bond with the Oc atom of Ser117 at a
distance of 3.0 A˚ (Ser117’ for the second inhibitor conformation)
and the carbon atom is oriented away from Ser117 (Ser117’) into
HBP3 or HBP3’. In HBP3 and 39, the methoxy group of the
inhibitor makes additional hydrophobic interactions with subunit
residues: Ala108 (Cb to OCH3 is 3.7 A˚) and Thr119 (C
c to OCH3
is 3.9 A˚). As with the structure of bound compound 11, the
hydrophobic side chains of the inner binding pocket residues of the
BD dimer (Ala108, Ala108’, Leu110, Leu110’, Thr119 and
Thr119’) stack with the aryl ring of the inhibitor. Interestingly,
in contrast to 11, water molecules (labeled W1 and W2 in
Figure 6b) are located between the Ser117 and Ser117’ residues of
the AC and BD dimers facilitating a hydrogen bonding network
through the Oc atom of Ser117 residues of all subunits. Ser117
and Ser117’ are also hydrogen bonded to the inhibitor. It should
be noted that the oxygen atom of the methoxy group of 13 does
not appear to be close enough to form a hydrogen bond (3.6 A˚
distance) with either water molecule. In both dimers, the linkers
are stabilized by the side chains of residues Leu17, Leu17’ (the
closest distance from the b carbon atom of the inhibitor is 3.5 A˚),
Ala108, and Ala108’ (3.8 A˚ distance from the nitrogen atom of the
inhibitor). The electron density map of all binding pocket residues
was clear and well ordered with the exception of the Lys15 and
Lys15’ in both the AC and BD dimers. With the best fit
conformation, the Lys15 and Lys15’ placed their Ne atom at
hydrogen bonding distance (2.9 A˚) from the carboxyl substituent
of the inhibitor. Like the TTR:11 structure, Thr119 of the AC
dimer maintains two conformations in the inner binding pocket
and interacts with the aryl ring of the inhibitor.
Binding of 15 to wt-TTR
Inhibitor 15 binds in the reverse binding mode by orienting its
carboxyl substituent towards the inner binding pocket (Figures 7a
and 7c) to interact with HBP3 and HBP3’ near Ser117-Ser117’.
The linker region of the inhibitor is only partially ordered in AC
Figure 6. Crystal structures of inhibitors 11 and 13 bound to TTR. (a) and (b) Electron density of 11 and 13 bound with both hormone
binding pockets of wt-TTR. Electron density of Shake&wARP [50] omit maps are contoured at the 1 s level. The blob feature in XtalView [49] was
applied to limit the electron density display to within 1.5 A˚ of the inhibitor and the final figure was rendered with Raster3D [51]. The inhibitor
molecules were omitted from the model before the map calculation. (c) The binding interactions of 11 with the hormone binding pocket of TTR, the
better ordered BD binding pocket is shown here. Like most of the TTR bound ligands, 11 also binds in two symmetry-related binding modes (shown
in magenta and green). The key interacting residues are labeled, primed and unprimed residues refer to two neighboring symmetry related
monomers comprising the T4 site. Compound 11 binds in the forward binding mode by orienting its carboxylate substituent to the outer binding
pocket residue Lys15. The aryl moiety of 11 is anchored by its trifluro group to HBP3 and HBP3’ of the inner most binding pocket. Like compound 11,
compound 13 also binds in the forward binding mode with similar interactions (not shown here).
doi:10.1371/journal.pone.0006290.g006
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dimer while the electron density corresponding to the BD dimer
inhibitor is well ordered as shown in Figure 7a. However, in both
hormone binding pockets the carboxyl group and fluorenyl moiety
occupy similar positions in both inner and outer binding pockets to
make comparable interactions with the residues near Ser117 and
Lys15 (Figures 7a and 7c). The fluorenyl ring moiety of the
inhibitor is located at the outer binding pocket formed by residues
Ala108, Lys15, Leu17, Thr106, and Val121 of both TTR
subunits. In contrast to the TTR:11 structure, all protomer
residues of the binding pocket, including Lys15, were well ordered
in the electron density map. Compared to the aryl compounds, the
bulky fluorenyl ring occupies the outer binding pocket more
extensively and forms several non-bonding interactions with the
protomer residues. The fluorenyl moiety of the inhibitor is
comfortably sandwiched in between the hydrophobic groups of
residues Lys15 (at the closest distance of 3.8 A˚ from the fluorenyl
ring), Lys15’, Leu17 (Cd1 at 3.3 A˚), Leu17’, Thr106 (Cc at 3.7 A˚),
Thr106’, Ala108 (Cb at 3.4 A˚), Ala108’, Val121 (Cc2 at 3.3 A˚) and
Val121’. In the dimer binding pocket, the fluorenyl ring is nearly
centered on the two-fold symmetry axis, giving the appearance of
a single binding conformation. However, the spacer maintains two
conformations (shown in magenta and green in Figures 7a and 7c)
and simultaneously interacts with Ser117 and Thr119 residues of
both HBP3 and HBP3’ of the inner binding pocket as detailed
below. In the inner binding pocket the carboxyl group forms four
hydrogen bonds per subunit. Both oxygen atoms of the carboxyl
group of 15 form hydrogen bonds with the side chain Oc of
Ser117 at distances of 2.7 and 2.8 A˚. Thr119 residue orients itself
towards the inhibitor and hydrogen bonds (Oc of Thr119 is at
2.8 A˚ distance from one of the carboxylate oxygen atoms) with
one of the oxygen atoms of the inhibitor carboxylate, also
positioning its Cb atom close to the inhibitor (the carbon alpha
atom to the carboxylate group of the inhibitor is at 3.6 A˚ distance).
Interestingly, a water molecule is located between the adjacent
Ser117 and Ser117’ residues at the two-fold axis and forms a
hydrogen bond with the carboxylate oxygen atom (3.1 A˚ distance)
and the Oc atom of Ser117 and Ser117’ (3.0 A˚ distance). Thus,
the reverse binding mode of 15 facilitates a network of hydrogen
bonds in the inner binding pocket connecting the Ser117 residues
of all subunits, the nearby water molecules, and the carboxylate
substituents of the inhibitor (Figures 7a and 7c). The alpha- and
beta-carbon atoms of the linker are also sandwiched between the
side chain atoms of Leu110 (the closest distance from the alpha
carbon atom of the linker is 3.8 A˚) and Leu110’ to further
augment the binding.
Binding of 16 to wt-TTR
Addition of an (S)-methyl group in the alpha position to the
carboxylic group of inhibitor 15 does not affect the binding mode
of the inhibitor. Compound 16 still maintains a reverse binding
Figure 7. Crystal structures of inhibitors 15 and 16 bound to TTR. (a) and (b) Electron density of 15 and 16 bound with both hormone
binding pockets of wt-TTR. Electron density of Shake&wARP [50] omit maps were contoured at the 1 s level. The blob feature in XtalView has been
applied to limit the electron density display to within 1.5 A˚ of the inhibitor and the final figure was rendered with Raster3D [51]. The inhibitor
molecules were omitted from the model before the map calculation. (c) The binding interactions of 15 with the hormone binding pocket of TTR, the
better ordered BD binding pocket is shown here. Inhibitor 15 also binds in two symmetry-related binding modes (shown in magenta and green). The
key interacting residues are labeled, primed and unprimed residues refer to two neighboring symmetry related monomers comprising the T4 site.
Compound 15 binds in the reverse binding mode by orienting its carboxylate substituent to the inner binding pocket and its fluroneyl ring to the
outer binding pocket. The fluroneyl ring is optimally sandwiched between the side chain atoms of the outer binding pocket, while the corboxylate
group makes a network of direct and water mediated hydrogen bonds. Leu110 and Leu110’ stack on top of the linker region but are not shown for
clarity. Compound 16 also binds in similar fashion (not shown here).
doi:10.1371/journal.pone.0006290.g007
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mode by pointing its linker toward the inner binding pocket and
placing its fluorenyl ring into the hydrophobic pocket formed by
residues Ala108, Lys15, Leu17, Thr106, and Val121. As in the
TTR:15 structure, the aliphatic linker of 16 takes on two
conformations with equal occupancy to simultaneously interact
with both HBP3 and HBP3’ residues (Figure 7b). Although the
outer binding pocket interactions are very similar for both 15 and
16, compound 16 shows notable differences in the binding
interactions at the inner binding pocket of TTR. Substitution of an
(S)-methyl group in the alpha position to the carboxylic group
kinks the carboxylic acid to the side of the inhibitor, into HBP3 or
HBP3’. As a result, in both conformations of the inhibitor, the
methyl substituent and the alpha- and beta-carbon atoms of the
linker are sandwiched between the side chain atoms of Leu110
and Leu110’; Cd2 of Leu110 is at 3.3 A˚ from the carbon alpha
atom to the carboxylic group of 16, the (S)-methyl carbon of 16 is
at 3.6 A˚ from Cd2 of Leu110, and Cb of Leu110 is at 4.0 A˚ from
the beta-carbon of 16. One of the oxygens of the carboxyl group
hydrogen bonds with the hydroxyl group of Ser117 (at a distance
of 2.6 A˚) and Oc atom of Thr119 (at a distance of 2.5 A˚). The
second conformation of the inhibitor is generated through
crystallographic two-fold symmetry and thus makes identical
interactions with the hormone binding pockets of TTR. Together,
the methyl substitution contributes to additional hydrophobic
interactions with the inner binding pocket of TTR. The W1 and
W2 water molecules observed between the Ser117 and Ser117’
residues of the TTR:15 structure are also conserved in TTR:16 (in
almost identical positions). However, the carboxylate group of the
inhibitors does not make any hydrogen bonds with the water.
Similar to the structures with bound 11, 13 and 15, the electron
density of the linker region is only partially visible in the AC
binding pocket.
Docking of b-aminoxypropionic acids to TTR
In an effort to complement our X-ray crystallographic studies
with molecular modeling exercises, we performed docking studies
of compounds 5–21 with the Gold v3.1 program (Cambridge
Crystallographic Data Centre), starting from the crystallographic
structure of the TTR-FLU complex (PDB ID: 1BM7 Klabunde,
2000 #16). For the arylideneaminoxy-derivative compounds 5–
14, the Gold program predicted the typical thyroxine orientation
(forward binding mode) using the Goldscore functions; The
aromatic ring is inserted into HBP3, and the b-aminoxyethyl chain
directs the carboxylic group towards Lys15, (see Figure 8a for
compound 11). In the docked structure, the ortho-CF3 substitution
on the phenyl ring is engaged in significant non-bonding
interactions with HBP3 residues Ala108, Leu110, Ser117 and
Thr119. However, substituents in the meta- and para- positions are
not predicted to interact with HBP3 to the same extent, since they
occupy the side part of this pocket. For 9-fluorenyliden-aminoxy
Figure 8. Docking of b-aminoxypropionic acids to TTR. (a) and (b) Schematic representation of compounds 11 (left) and 15 (right) in one of
the TTR hormone binding sites shown with the best docking results of compounds 11 and 15, evidencing the HBP3 surface; both possible binding
modes are shown for 15 (red and black). (c)–(e) Gold docking results. (c): front view of compounds 16 (magenta) and 17 (green), depicting the HBP3
surface and Lys15 of A and C monomers, (d): side view of compound 20, (e): front view of compound 24, (f): front view of compound 26.
doi:10.1371/journal.pone.0006290.g008
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derivatives 15–17 and 20, the Gold program suggested the reverse
binding modes (see Figures 8b, 8c and 8d) using Goldscore
functions. The TTR:15 and TTR:11 crystal structure reveals that
15 binds to the hormone binding pocket in the reverse binding
mode and 11 bind in the forward binding mode with an
orientation similar to the one obtained through the Goldscore
algorithm. Therefore, this docking protocol was subsequently used
to predict the binding of all other b-aminoxypropionic derivatives.
The 9-fluorenyliden-aminoxy derivatives 16 and 17 may be
placed in a reverse binding mode (Figure 8c). Only compound 16
reveals an effective interaction with HBP3. The corresponding (R)-
enantiomer 17 inserts the methyl substituent into HBP3, and
directs the carboxylic group away from the Ser117 or Ser117’
residue, without any productive interactions. Interestingly, the
hypothesized binding mode for compound 20 (Figure 8d) is
different from the other inhibitors; the molecule interacts with
HBP3 and HBP3’ simultaneously, through the carboxylic moiety
and the aminoxymethyl chain, respectively. Based on the docking
analysis of compounds 5–21, we have also evaluated the docking
of two potent b-aminoxy-N-(methylsulfonyl) propionamides (com-
pounds 24 and 26) to TTR hormone binding pocket using
Goldscore algorithm. As shown in Figure 8e the aryl compound
24 predicted to bind in a forward binding mode while the
fluorenyl analog 26 binds in the reverse binding mode (Figure 8f)
with extended interactions in HBP3s and HBP1s respectively.
Discussion
The majority of previously reported TTR amyloid inhibitors,
including diflunisal, are halogenated compounds designed to
occupy one or more TTR hormone binding pockets [8]. With
several potent biaryl families of TTR inhibitors available, the
current drug discovery initiatives have targeted diverse chemo-
types, focusing on various amyloidogenic conditions, including
TTR-mutant amyloidosis, sparing off-target anti-inflammatory
activity, and reducing the toxic effects of long-term NSAID
administration. Recently published studies have focused on
optimizing the aryl halogen substituent(s) [42], the linker between
the two aryl rings [43] and minimization of cyclooxygenase (COX)
inhibition (a common unwanted side effect of TTR inhibitors)
[34,38]. However, these studies were solely focused on haloge-
nated biaryl compounds. It is interesting to note that among all
compounds tested here, the most potent inhibitors (compounds 15,
16, 20 and 27) are from the non-halogenated fluorenyl family,
while the phenyl-substituted relatives (2 halogenated and 2 non-
halogenated) showed comparatively lower inhibition. We seek to
further discuss these findings, their correlation with inhibitor
binding mode, and reflect on their significance with regard to
known inhibitors. In particular, it is noteworthy that the fluorenyl
family constitutes a novel class of TTR fibrillization inhibitors.
Insight from aryl analogs
The chemical structures of 11, 13 and all other aryl derivatives
discussed in Table 1 may be compared with the previously reported
bisaryloxime ethers, potent inhibitors of TTR [39]. For example, 4-
carboxybenzaldehyde-O-(2-trifluoromethylphenyl)-oxime (OE1)
showed more than 90% inhibition at a 7.2 mM concentration
against acid mediated fibrils of 3.6 mM TTR. The TTR:OE1
crystal structure is shown in Figure 9a [39]. This inhibitor contains
an ortho-trifluoromethylphenyl O-linked through an oxime with a
para-substituted benzoic acid and binds to TTR in the forward
binding mode. Similar to the TTR:OE1 crystal structure, inhibitors
Figure 9. Comparison of the TTR:11 and TTR:15 structures with the TTR:OE1, TTR:DDBF, and TTR:PHENOX structures. (a) Overlay of
the binding pocket of previously published TTR:OE1 (shown in orange red [39]) on the TTR:11 crystal structure. Residues Ser117 and Ser117’ point to
the inner binding pocket while Lys15, Lys15’, Glu54, and Glu54’ denote the outer binding pocket of one of the T4 sites of TTR. The two binding
conformations of 11 are shown in light and dark green stick format. Compared to OE1, 11 binds more deeply in the inner binding pocket and
positions its carboxyl group closer to the outer binding pocket residue Lys15. (b) Overlay of the binding pocket of TTR:DDBF [22] and TTR:PHENOX
[22] on the TTR:15 crystal structure. Residues Ser117 and Ser117’ point to the inner binding pocket while Lys15, Lys15’, Glu54, and Glu54’ denote the
outer binding pocket of one of the T4 sites of TTR. The two binding conformations of 15 are shown in light and dark green stick format, PHENOX is
shown in red and orange sticks. Both binding conformations of DDBF are shown in thin black sticks. The DDBF binds mainly to HBP1 near Lys15
while PHENOX extended its interaction from Glu54 to HBP2. The new compound 15 effectively utilizes all the HBPs located between Lys15 and
Ser117. Suitable substitution in the fluorenyl ring of 15 should cover the entire binding pocket starting from Glu54 to Ser117.
doi:10.1371/journal.pone.0006290.g009
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11 and 13 bind in the typical forward binding mode by pointing
their carboxylate functionality towards the outer binding pocket
residues Lys15 and Lys15’ (Figure 6). In contrast to the bisaryloxime
ethers, the inhibitors reported here only contain a single aryl group
and the carboxyl group is directly tethered through a flexible linker.
Compared to OE1, inhibitors 11 and 13 bind more deeply in the
inner binding pocket of TTR (Figure 9a). In the TTR:OE1
structure, the halogenated phenyl ring moves away from the inner
binding pocket and does not make significant interactions with the
Ser117 and Ser117’. For inhibitors 11 and 13, the aryl ring makes
both hydrophobic and hydrogen bond interactions with Ser117,
Ser117’, Thr119, and Thr119’ residues and points its ortho-
substituent into the center of the HBP3 and HBP3’ pockets. Taken
together, the X-ray crystal structural data demonstrate that, like the
OE1 bis(aryl) family, compounds 11 and 13 can bind to TTR in the
forward binding mode. However, the aryl family reported herein
has the advantage of more fully occupying the inner hormone
binding pockets, further stabilizing the native tetrameric structure
and, in turn, inhibiting amyloid formation.
In the in vitro fibril formation assay, inhibitors 11 and 13 showed
43% and 51% inhibition, respectively, at a 3.6 mM concentration
against an equimolar concentration of TTR. Analysis of the fibril
inhibitory activity for our somewhat small set of aryl analogs
suggests that TTR inhibition scales with the size of the ortho-
substituent, with 11 (CF3) and 13 (OMe) having the largest groups
at this position. Based on X-ray structural data and docking, the o-
CF3 or o-OMe group is able to interact with HBP3 and HBP3’
residues Ala108, Leu110, Ser117 and Thr119. When this moiety is
in the meta- or para- position, these interactions with HBP3 appear
to be lost, resulting in a loss of activity (cf. compounds 10 and 14
of Table 1). BBased on the crystal structures, docking studies and
SAR for the aryl class, we propose that further optimization of the
ortho-substituted aryl ring may be achieved through the direct
substitution of a halogen atom at the 5-position of the aryl ring
which will protrude into the HBP3’ while the CF3 is still anchoring
at HBP3 position. In addition, placement of a hydrogen bond
donor and/or acceptor, i.e. hydroxyl, at the meta- or para-position
may lead to enhanced interactions with Ser117/Ser117’ and, thus,
enhanced inhibitory activity.
Based on the inhibitor efficacy data of aryl compounds 22, 23,
24, 28, 29, and 31 it is clear that further lengthening of the linker
affects TTR fibril formation. Compounds 22, 23, 28, 29, and 31
with an aryl moiety substituted with either meta-Me, meta-F, 3,4-
OCH2O, or the acid isostere CONHSO2CH3, did not exhibit
significant activity. However, compound 24, featuring an ortho-
trifluoromethyl group and the CONHSO2CH3 modification of
the linker, showed a 13% improvement in fibril inhibition activity
over 11. Based on the docking analysis (Figure 8e), the ortho-CF3
group was predicted to be critical for anchoring the aryl moiety of
24 to the inner binding pocket, favoring the forward binding
mode. Interestingly in the outer binding pocket, the acylsulfona-
mide moiety of 24 may mimic the negative charge of the
carboxylate in 11, while having the potential to make additional
hydrogen bonds with Lys15 and Lys15’ residues. The sulfonamide
pendant methyl group may also interact with the HBP1 and
HBP1’ pockets of the TTR outer binding pockets. Clearly, further
optimization of the terminal carboxylic acid/acid isostere, in
conjunction with continued examination of the role of the ortho-
aryl substituent, will be necessary to clarify the precise structural
requirements for enhanced inhibition of fibrillization.
Insight from the fluorenyl compounds
Compared to the aryl family, the fluorenyl derivatives presented
herein do not have close analogs that have previously been well-
characterized as TTR inhibitors. Dibenzofuran-4,6-dicarboxylic
acid (DDBF) [22] and m-trifluoromethyl-substituted N-aryl
phenoxazine (PHENOX) have been explored with the hypothesis
that the bulkier tricyclic moieties should bind with higher affinity
to the TTR hormone binding pocket [22]. The TTR:DDBF co-
crystal structure showed that the tricyclic ring of DDBF effectively
utilizes the hydrophobicity of the outer binding pocket and binds
in a forward binding mode, orienting its directly linked carboxyl
moiety towards Lys15. However, the inner binding pocket is
completely unoccupied (Figure 9b), and as a result DDBF
exhibited only moderate inhibition (46%) at a 3.6 mM concentra-
tion [22]. Substituting a halogenated aryl ring for one of the
benzene rings of DDBF increased its inhibitory activity to ,70%
[22], but the binding mode has yet to be explored [22]. In the case
of the TTR:PHENOX structure [22], the inhibitor binds in the
outer binding pocket between Glu54 and Thr119 (Figure 9b). The
biaryl system facilitated additional hydrophobic interactions with
the HBP1 residues (Figure 9b) and positioned its carboxyl group
close to Glu54 to form additional hydrogen bond interactions,
resulting in an improved fibrillization inhibition [22] of 73%
inhibition at 3.6 mM. The fluorenyl compounds presented in
Table 1 constitute a new class of inhibitors as they can span the
entire binding pocket and simultaneously interact with both the
inner and outer binding pockets. In the TTR:15 and TTR:16
structures, the tricyclic moiety of the inhibitor completely fills the
outer binding pocket and the carboxylated chain adopts two
conformations to interact with both the HBP3 and the HBP3’
residues of the inner binding pocket. Consequently, a water-
mediated hydrogen bonding network is enabled, engaging
neighboring TTR subunits AC and BD (Figure 7). The fluorenyl
(outer pocket)-tether (linker space)-carboxyl (inner pocket) archi-
tecture of 15 and 16 fully occupies the space between Lys15 and
Ser117 and stabilizes the tetrameric structure of TTR by tethering
each of its subunits through numerous interactions. The fluorenyl
moiety is sandwiched between the hydrophobic groups of residues
Lys15, Lys15’, Leu17, Leu17’, Thr106, Thr106’, Ala108, Ala108’,
Val121 and Val121’ in the outer binding pockets of both AC and
BD dimer. The carboxyl group simultaneously interacts with
Ser117 and Thr119 residues of both HBP3 and HBP3’ and
facilitates a network of hydrogen bonds in the inner binding pocket
connecting the Ser117 residues of all subunits, the nearby water
molecules, and the carboxylate substituents of all the inhibitors. In
addition, the linker carbon atoms are also sandwiched between the
side chain atoms of Leu110 and Leu110’ to further augment the
inhibitor protomer interactions. Thus, 15 and 16 exhibit
approximately 70% inhibitory activity at 3.6 mM concentration
and more than 90% inhibitory activity at 7.2 mM against 3.6 mM
TTR fibrils. It is interesting to note that the R-enantiomer (17) of
the most potent inhibitor (16) of this series is completely inactive,
suggesting that the conformation of the linker is critical for the
activity of 16. This is, however, not the case with the modified
linker compounds 26 and 27, in which the activity remained
similar for both S- and R-enantiomers.
The X-ray structural data demonstrate that the aromatic group
(phenyl or fluorenyl) is what determines the binding mode of the
TTR inhibitor in this series. Particularly, the complementarity of
the fluorenyl moiety to the outer binding pocket supports this
conclusion. The two-carbon linker of 15 compliments the reverse
binding of fluorenyl derivatives and yielded the most potent
compound of this series. It is interesting to note that alterations to
the linker, including stereodefined a-methylation (to afford 16 and
17) and introduction of an a-methoxyimino moiety (to afford 20),
did not improve inhibition of fibrillization. Clearly, the stereo-
chemistry of the appended a-methyl group is important and this
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information should be of utility in future designs. The limited
number of replacements for the terminal carboxylic acid in the
fluorenyl series produced mixed results. In the case of substitution
of the acid with an acylsulfonamide, we observed a complete loss
of activity (15 versus 25), maintenance of inhibition (16 versus 26),
and significant gain of efficacy (17 versus 27). Clearly, a larger
subset of compounds will be required to clarify this SAR along
with the critical structural insights that X-ray crystallography can
provide. Similar efforts may also allow us to realize benefit from
the use of amide-acid termini, such as in 30 and 31, which
currently do not exhibit a benefit compared to the carboxylic acid
terminated 15. Furthermore, we will seek to examine the role of
substitutions on both the fluorenyl ring and two-carbon linker of
15 to further optimize this potent class of fibrillization inhibitors.
Concluding remarks
Previous studies have shown that diverse families of biaryl
compounds possess potent inhibitory activity against TTR
amyloidosis. We have evaluated a novel family of inhibitors,
featuring an aryl or fluorenyl substituent tethered through a
flexible oxime to a carboxylic acid, or methylsulfonamide group.
Of the 28 compounds tested, based on the in vitro fibril formation
assay, eight compounds showed significant inhibition of TTR
amyloidogenesis at a concentration of 3.6 mM, equal to the
concentration of tetrameric wt-TTR. The x-ray crystal structures
of the TTR–inhibitor complexes presented here illustrates the key
molecular features for inhibitor binding and provide the structural
basis for the stabilization of the native tetrameric TTR. The
crystallographic and docking studies also suggest that the aryl
compounds prefer the forward binding mode and the flurorenyl
analogs orient in a reverse binding mode. Analysis of the
TTR:inhibitor complexes reveals the advantage of the fluorenyl
group over the aryl moiety, in combination with the flexible oxime
based tether, in tetramer stabilization. With regard to further
diversification from T4, none of these fluorenyl compounds,
including four potent TTR amyloid inhibitors, contain halogen
substitutions, in striking contrast to the majority of previously
reported biaryl inhibitors. Fluorenyl compound 15 exhibited the
best activity, reducing fibril formation by nearly 70% at 3.6 mM
concentration and 95% at 7.2 mM concentration. Another
important advantage of 15 is that it is devoid of anti-inflammatory
activity in an in vivo carrageenan-induced paw edema assay in rats
[31,33]. This selectivity, in contrast to NSAID-based TTR
inhibitors such as Flu, is hypothesized to derive from the bulky
nature of the fluorenyl moiety. The bulkier fluorenyl system may
render 15 incompatible with the comparatively smaller COX
enzyme binding pockets (Supplementary Figure S2). Thus, 15 may
represent a good starting point for a new family of compounds that
stabilize the TTR tetramer, while sparing off-target anti-
inflammatory activity and reducing the toxic effects of long-term
NSAID administration.
Materials and Methods
Chemistry
Melting points were determined on a Kofler hot-stage apparatus
and are uncorrected. 1H NMR spectra of all compounds were
obtained with a Gemini 200 spectrometer operating at 200 MHz,
in a ca. 2% solution of CDCl3. Analytical TLCs were carried out
on 0.25 mm layer silica gel plates containing a fluorescent
indicator; spots were detected under UV light (254 nm). Mass
spectra were detected with a Hewlett Packard 5988A spectrom-
eter. Evaporation was performed in vacuo (rotating evaporator);
Na2SO4 was always used as the drying agent. Elemental analyses
(C, H, N) were performed in our analytical laboratory and agreed
with theoretical values to within60.4%.
General procedure for the synthesis of the
propionamides 22–27
A solution of the appropriate b-aminooxy acid A (1.19 mmol)
and the methanesulfonamide (1.19 mmol) in anhydrous DMF
(3 mL) was stirred at r.t. under N2 atmosphere, in presence of
DCC (1.19 mmol) and a catalytic amount of DMAP
(0.119 mmol), until the disappearance of the starting carboxyl
compound (TLC, 48 h). After this time the mixture was taken up
with Et2O, cooled at 0uC for 50 minutes and the resulting solid
precipitate was filtered. The Et2O solution was acidified with
acetic acid and washed with H2O and brine. Evaporation of the
organic layer afforded a residue, which was crystallized from
appropriate solvents to give the pure desired compounds 22–27:
(E)-N-(methylsulfonyl)-3-(3,4-methylendioxy)-(benzyliden-
eaminooxy)-propionamide (22). (45%) m.p 130–131uC
(CHCl3–hexane);
1H NMR 2.82 (t, 2H, J = 5.2 Hz), 3.31 (s, 3H) ,
4.42 (t, 2H, J = 5.2 Hz) 6.02 (s, 2H), 6.80–7.23(m,3H) , 8.04(s, 1H),
9.28(brs, 1H). C12H14N2O6S (C, H, N).
(E)-N-(methylsulfonyl)-3-(3-methyl-benzylideneaminooxy)
propionamide (23). (45%) m.p 107–108uC (hexane); 1HNMR
2.29 (s, 3H), 2.84 (t, 2H, J = 5.4 Hz), 3.31 (s, 3H), 4.46 (t, 2H,
J = 5.4 Hz), 7.30–7.46 (m, 4H), 8.11(s, 1H), 9.10(brs, 1H).
C12H16N2O4S (C, H, N).
(E)-N-(methylsulfonyl)-3-(2-trifluoromethyl-benzylidenea-
minooxy)-propionamide (24). (40%) (CHCl3–hexane) m.p
116–118uC 1H NMR 2.83 (t, 2H, J = 5.4 Hz), 3.29 (s, 3H) , 4.52
(t, 2H, J = 5.4 Hz), 7.32–7.45 (m, 3H) ,7.99–8.01(m, H), 8.45 (s,
1H), 9.45(br s, 1H). C12H13F3N2O4S (C, H, N).
3-(9-fluoren-9-ylideneaminooxy)-N-(methylsulfonyl)propi-
onamide (25). (20%) m.p 173–174uC (i-PrOH) 1H NMR 2.96 (t,
2H J = 5.4 Hz), 3.26 (s, 3H, ), 4.71(t, 2H, J = 5.4 Hz), 7.31–7.64 (m,
6H), 7.82(d, 1H, J = 7.6 Hz), 8.21(d, 1H, J = 7.6 Hz) 9.25(brs, 1H).
C17H16N2O4S (C, H, N).
(S)-(26) and (R)-(27) 3-(9-fluoren-9-ylideneaminooxy)-2-
methyl-N-(methylsulfonyl) propionamides. (S)-26 (35%)
[a]D
22+4.2 (CHCl3, c = 1.18); and (R)- 27 (30%) [a]D2224.8
(CHCl3, c = 1.09); m.p 182u–183uC (CH2Cl2-hexane )
1H NMR
1.32(d, 3H, J = 7.0 Hz), 3.07 (m, 1H), 3.22 (s, 3H), 4.54 (m, 2H),
7.26–7.67 (m, 6H), 7.78(d, 1H, J = 7.4 Hz), 8.20(d, 1H,
J = 7.4 Hz), 8.90(br s, 1H). C18H18N2O4S (C, H, N). The
compounds (S)-26 and (R)-27 possess an enantiomeric purity
.96% determined by 1H NMR analysis using (R)-cinconidine as a
chiral resolving agent. An equimolar mixture of (S)-(26)- and (R)-
(27)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl)
propionamides with (R)-cinconidine in CDCl3 displayed in its
1H
NMR spectrum two doublets at 1.25 and 1.21 ppm, attributable
to 2-methyl protons of (R)-27 and (S)-26 stereoisomers,
respectively.
General procedure for the synthesis of the ethyl esters
33–37
To a solution of appropriate b-aminooxy acid A (3.58 mmol) in
anhydrous DMF (28.0 mL) in the presence of Et3N (1.5 mL) was
added portionwise the glycine ethyl ester hydrochloride
(3.78 mmol) or b2alanine ethyl ester hydrochloride and TBTU
(O-benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium tetrafluoro-
borate, 8.4 mmol). The resulting solution was stirred at r.t. for
4 h. After this time the mixture was taken up with AcOEt and
washed with H2O, a solution of 5% aqueous NaHCO3, an
aqueous solution of 0.1 M HCl, and brine. Evaporation of the
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dried organic layer afforded a residue which was crystallized from
appropriate solvents to give the pure desired compounds 33–37 :
(E)-ethyl 2-(3-(3,4-methylenedioxy)-benzylideneaminoxy) pro-
panamido)acetate (33): (50%) m.p 90–91uC (i-Pr ether), 1H
NMR 1.27 (t, 3H, J = 6.4 Hz), 2.86 (t, 2H, J = 5.4 Hz), 4.03–
4.47 (m, 6H), 5.95 (s, 2H ), 6.35(br s,1H), 6.72–7.30 (m, 3H), 7.97
(s, 1H). C15H18N2O6 (C, H, N).
(E)-ethyl 2-(3-(4-fluoro)-benzylideneaminoxy) propanamido)ace-
tate (34): (52%) m.p. 102–103uC (CHCl3-hexane)
1H NMR 1.26
(t, 3H, J = 6.4 Hz), 2.87 (t, 2H, J = 5.6 Hz), 4.03–4.47 (m, 6H),
6.35 (br s,1H), 6.09–7.51 (m, 4H) 8.04 (s, 1H). C14H17FN2O4 (C,
H, N).
Ethyl 2-(3-9H-fluoren-9-ylideneaminoxy) propanamido)acetate
(35): (71%) m.p 99–100uC (i-Pr ether-hexane). 1H NMR 1.22 (t,
3H, J = 6.4 Hz), 2.80 (t, 2H, J = 5.6 Hz), 3.97–4.26 (m, 4H), 4.67
(t, 2H, J = 5.6 Hz), 6.25 (br s,1H), 7.12–7.88 (m, 7H), 8.21 (d, 1H,
J = 7.6 Hz). C20H20N2O4 (C, H, N).
(E)-ethyl 3-(3-(3,4-methylendioxy)-benzylideneaminoxy) propa-
namido) propanoate (36): (45%) m.p 72u–73uC (hexane), 1H
NMR 1.23 (t, 3H, J = 6.4 Hz), 2.6 (m 4H), 3.51 (q, 2H,
J = 5.6 Hz), 4.01 (q, 2H J = 6.4 Hz), 4.36 (q, 2H J = 5.6 Hz),
5.96 (s, 2H, ), 6.40 (brs,1H), 6.80–7.21 (m, 3H), 7.95 (s, 1H).
C16H20N2O6 (C, H, N).
Ethyl 3-(3-9H-fluoren-9-ylideneaminoxy) propanamido) pro-
panoate (37): (55%) m.p 115u–116uC (CHCl3-hexane),
1H NMR
1.14 (t, 3H, J = 6.4 Hz), 2.44 (t, 2H, J = 6.4 Hz), 2.72 (t, 2H,
J = 5.6 Hz), 3.50 (q, 2H, J = 6.4 Hz), 3.95 (q, 2H J = 7.2 Hz), 4.65
(t, 2H, J = 5.6 Hz), 6.40 (br s, 1H), 7.22–7.78 (m, 7H), 8.17 (d, 1H,
J = 7.6 Hz). C21H22N2O4 (C, H, N).
General procedure for the synthesis of the acids 28–32
To a solution of ethyl esters of acetate derivatives 33–35 or the
ethyl esters of propanoate derivatives 36, 37 (0.93 mmol) in
EtOH/H2O (1:1, 6 mL) was added a solution of solid KOH
(0.025 mmol) in EtOH (8 mL). After 24 h at r.t., the solvent was
evaporated and the residue was taken up with H2O and washed
with Et2O. The aqueous layer was acidified to pH 4 with 10%
aqueous HCl and then extracted with Et2O. Evaporation of
washed (H2O) and dried organic layer gave a solid residue which
was crystallized from the proper solvent to give pure 28–32:
(E)-2-(3-(3,4-methylendioxy)-benzylideneaminoxy) propanami-
do)acetic acid (28): (30%) m.p. 110u–112u (hexane). 1H NMR
2.68 (t, 2H, J = 5.6 Hz ), 4.0, 4.06 (d, 2H, J = 4.8 Hz), 4.39 (t, 2H,
J = 5.6 Hz), 5.95 (s, 2H) 6.55 (br s,1H), 6.71–7.24 (m, 4H), 7.99 (s,
1H). C13H14N2O6 (C, H, N).
(E)-2-(3-(4-fluoro)-benzylideneaminoxy)propanamido)acetic ac-
id (29): (45%) m.p 126–128uC (hexane). 1H NMR 2.65 (t, 2H,
J = 5.6 Hz), 3.99 (d, 2H, J = 4.8 Hz) 4.42 (t, 2H, J = 5.6 Hz) 6.60
(br s,1H) 6.90–7.72 (m, 4H), 8.03 (s, 1H). C12H13FN2O4 (C, H, N)
2-(3-9H-fluoren-9-ylideneamiooxy)propanamido)acetic acid
(30): (71%) m.p 104u–105uC (i-Pr ether).1H NMR 2.79 (t, 2H,
J = 5.6 Hz), 3.97 (d, 2H, J = 4.8 Hz), 4.66 (t, 2H, J = 5.6 Hz), 6.60
(br s,1H), 7.12–7.88 (m, 7H), 8.20 (d, 1H, J = 7.6 Hz).
C18H16N2O4 (C, H, N).
(E) 3-(3-(3,4-methylendioxy) benzylideneaminoxy) propanami-
do)propanoic acid (31): (40%) m.p 85u–87uC (hexane).1H NMR
2.48–2.67(m, 4H), 3.51(q, 2H, J = 5.6 Hz), 4.35 (t, 2H, J = 5.6 Hz
), 5.94 (s, 2H ), 6.55 (brs,1H), 6.67–7.21 (m, 3H) 7.93 (s, 1H).
C14H16N2O6 (C, H, N).
3-(3-9H-fluoren-9-ylideneamiooxy) propanamido) propanoic
acid (32): (45%) m.p 112u–114uC (CHCl3, hexane).
1H NMR
2.40–2.79(m, 4H), 3.53(q, 2H, J = 5.6 Hz), 4.65(t, 2H, J = 5.6 Hz),
6.55 (br s,1H), 7.26–7.67 (m, 8H) . C19H18N2O4 (C, H, N).
The E configuration around the C = N double bond of the b-
aminoxy-N-(methylsulfonyl)propionamides 22–24, the (b-ami-
noxy-propanamido)-acetic acids 28,29 and the propanoic acid
31 was assigned on the basis of the knowledge of the configuration
of starting acids and on the basis the observation that in their 1H
NMR spectra the proton linked to the oxymic carbon atom,
resonates at chemical shift values identical or very close to those of
the same proton of starting acids of E configuration
Molecular modeling
The crystal structure of the TTR:FLU dimeric complex (PDB
ID: 1BM7 [27]) was used to generate the correspondent tetramer
through the Unit Cell Tool of the Chimera program [44]. All of
the inhibitors were submitted to a conformational search of 1000
steps with a 2 kcal/mol energy window and then minimized using
the conjugated gradient method until a convergence value of
0.05 kcal/mol by means of the MACROMODEL (Macromodel,
ver. 8.5; Schro¨dinger Inc.: Portland, OR, 1999) program. The
algorithm used was the Monte Carlo method with MMFFs as the
force field and a distance-dependent dielectric constant of 4.0. The
docking studies were carried out through the standard mode of
GOLD 3.1 [45], which uses a genetic algorithm search strategy. A
binding site was defined as all atoms of TTR within 5 A˚ of the
FLU, and the Cavity Detection algorithm [46] was enabled. The
number of generated poses was set to 20, without the early
termination option, and the default calculation mode was selected.
By default, the GA (Genetic Algorithm) run comprised 100,000
genetic operations on an initial population of 100 members
divided into five subpopulations, and the annealing parameters of
the fitness function were set at 3.0 for van der Waals and 2.5 for
hydrogen bonding. The two fitness functions implemented in
Gold, GoldScore was used to identify the better binding mode.
Fibril formation assay
Wild-type TTR was purified from an E. coli expression system
and the rate of acid-mediated fibril formation and inhibitor
efficacy of each compound was determined by monitoring the
turbidity of wt-TTR at pH 4.4, as described previously [22,25,27].
Each compound was dissolved in DMSO at a concentration of
720 mM starting from a primary stock solution of 7.2 mM. Five
microliters of a solution of the compound being evaluated was
added to 495 mL of a 7.2 mM TTR solution in 10 mM phosphate
(pH 7.6), 100 mM KCl, 1 mM EDTA buffer, allowing the
compound to incubate with TTR for 30 min at room tempera-
ture. Five hundred microliters of 200 mM acetate buffer (pH 4.2),
100 mM KCl, 1 mM EDTA was added to yield final TTR and
inhibitor concentrations of 3.6 mM each and a final pH of 4.4. The
final 1 mL mixture was vortexed, then incubated at 37uC for
72 hr, after which the tubes were vortexed, and the optical density
was measured at 400 nm in a disposable UV cuvette. All assays
were performed in triplicate. The percentage of fibril formation
was determined by normalizing each optical density by that of
TTR without inhibitor, defined to be 100% fibril formation.
Control solutions of each compound in the absence of TTR were
tested, all compounds were soluble and none absorbed appreciably
at 400 nm, ensuring that turbidity was the result of TTR amyloid
formation.
X-ray Data collection and structure determination
Crystals of wt-TTR were obtained from 5–7 mg/mL protein
solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium
phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against
2 M ammonium sulfate in hanging drops. All TTR:ligand
complexes were prepared from crystals soaked with a fivefold
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molar excess of ligand for 3–4 weeks to ensure saturation of both
binding sites without affecting the diffraction quality of the crystals.
An R-axis IV++ detector coupled to an Rigaku Micromax 007
rotating anode X-ray generator was used for data collection of all
four complex structures. A single crystal was placed in paratone oil
as a cryoprotectant and cooled to 120 K for diffraction
experiments. Crystals of all TTR:ligand complex structures are
isomorphous with the apo crystal form with the space group
P21212 with two subunits in the asymmetric unit (Table 3). All
data sets were processed and scaled with the Crystal Clear suite
(Rigaku Corporation).
Structure refinement
The protein atomic coordinates for wt-TTR from the Protein
Data Bank (accession number 1BMZ [27]) were used as a starting
model during the rigid body refinement in CCP4-Refmac [47,48].
For each binding pocket of the TTR tetramer, the resulting
difference Fourier maps revealed two ligand-binding conforma-
tions. The electron density corresponding to the inhibitor observed
in the inner and outer hormone binding pockets of the BD dimer
was well ordered in all TTR:ligand crystal structures (Figures 6
and 7). In contrast, the electron density of the carboxyl substituted
region of these inhibitors was only partially ordered in the AC
dimer. However, the ligands could be unambiguously placed into
the existing density of both hormone binding pockets and were
included in the crystallographic refinement. The subsequent map-
fitting was done in XtalView/Xfit [49] using the unbiased
weighted electron density map calculated by the Shake&wARP
bias removal protocol [50]. All binding conformations of the
ligand were in good agreement with the unbiased annealed omit
maps as well as the Shake&wARP unbiased weighted maps phased
in the absence of the inhibitor. Final cycles of the refinement were
carried out by the maximum likelihood restrained refinement
protocol of CCP4-Refmac [47]. Due to the lack of interpretable
electron densities in the final map, the nine N-terminal and three
C-terminal residues were not included in the final model. A
summary of the crystallographic analysis is presented in Table 3.
Water molecules were identified using XtalView/Xfit. The figures
were prepared using XtalView [49], Raster3D [51] and UCSF
Chimera [44]. The atomic coordinates of the TTR inhibitor
complexes have been deposited in the Protein Data Bank with the
codes 3GLZ, 3GS7, 3GS4, and 3GS0.
Supporting Information
Figure S1 Chemical scheme for the synthesis of compounds 22–
32.
Found at: doi:10.1371/journal.pone.0006290.s001 (0.05 MB PPT)
Figure S2 Side by side comparison of the binding pockets of
TTR:15 structure and the prostaglandin binding channel of
COX-2 (PDB 3PGH). Left: Hormone binding channel of TTR
with bound 15, the halogen binding pockets are labeled according
to the manuscript. Right: Binding of the flurbiprofen (FLP) into
the prostaglandin binding channel of COX-2 (PDB 3PGH). The
binding channel has two entrances, one on the top and one on the
left. The COOH group of flurbiprofen is positioned at one of the
entries close to residue Arg120 and thus allows the formation of a
salt bridge. As in the TTR:biphenyl compounds, the protein:li-
gand interactions are augmented by hydrophobic interactions
between the biphenyl moiety of the drug and hydrophobic protein
residues. In contrast to Flu, the newly designed compounds based
on bulkier 15 are less compatible with the COX enzyme binding
pockets.
Found at: doi:10.1371/journal.pone.0006290.s002 (0.68 MB
DOC)
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